20-Mar-2026
No headlines found.
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
Globe Newswire (Tue, 24-Feb 8:00 AM ET)
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Globe Newswire (Thu, 5-Feb 8:00 AM ET)
Cabaletta Bio Announces 2026 Strategic Priorities
Globe Newswire (Mon, 12-Jan 8:00 AM ET)
Business Wire (Mon, 12-Jan 7:30 AM ET)
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Cabaletta Bio trades on the NASDAQ stock market under the symbol CABA.
As of March 20, 2026, CABA stock price declined to $2.94 with 1,608,262 million shares trading.
CABA has a beta of 3.83, meaning it tends to be more sensitive to market movements. CABA has a correlation of 0.28 to the broad based SPY ETF.
CABA has a market cap of $283.02 million. This is considered a Small Cap stock.
Last quarter Cabaletta Bio reported $0 in Revenue and -$.44 earnings per share. This fell short of revenue expectation by $-833,330 and exceeded earnings estimates by $.03.
In the last 3 years, CABA traded as high as $26.35 and as low as $.99.
The top ETF exchange traded funds that CABA belongs to (by Net Assets): VTI, VXF, IBB, IWC, PRFZ.
CABA has outperformed the market in the last year with a return of +68.0%, while the SPY ETF gained +16.6%. In the last 3 month period, CABA beat the market returning +23.0%, while SPY returned -4.4%. However, in the most recent 2 weeks CABA has underperformed the stock market by returning -7.3%, while SPY returned -3.3%.
CABA support price is $2.87 and resistance is $3.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CABA shares will trade within this expected range on the day.